{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T13:34:47Z","timestamp":1771076087357,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Risk communication is necessary to improve the booster vaccination rate, but Vietnam does not have a system to collect and disclose such information. Therefore, the purpose of this study was to clarify adverse reactions and their frequency in the early period after booster vaccination, and to obtain primary data for improving the booster vaccination rate. Methods: A cross-sectional survey was conducted among adults aged \u226518 years. Clinical data were collected 14 days after booster vaccination by using a standard questionnaire. Results: A total of 1322 participants were included with median age = 23 and sex ratio (Male\/Female) = 0.53. AstraZeneca was the most commonly used vaccine for the first and second doses, while Pfizer was the most commonly used vaccine for booster shots. Injection site pain, fatigue, and myalgia were the most common side effect reported (71.9%, 28.1%, and 21.8%, respectively). Compared to previous COVID-19 vaccine injections, 81.9% of participants reported that their symptoms were similar or milder after receiving the booster dose. They were more likely to present injection site pain (OR = 1.43, p &lt; 0.0001) and lymphadenopathy (OR = 4.76, p &lt; 0.0001) after receiving the booster shot. Fever (OR = 0.33, p &lt; 0.0001) and fatigue (OR = 0.77, p = 0.002) were less often reported after booster shots compared to the first and second injections. The severity of symptoms occurring after booster dose versus first and second doses increased significantly with each additional year of age and among participants receiving the Pfizer and Moderna vaccines. Conclusion: Adverse reactions to booster vaccination are minor and their incidence is the same as for the first or the second vaccination. Multicenter studies with larger sample sizes on the side effects and safety of COVID-19 vaccine booster shots need to be conducted to make the population less worried, in order to increase the vaccination rate, to protect individuals\u2019 and communities\u2019 health.<\/jats:p>","DOI":"10.3390\/vaccines10081325","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T03:15:27Z","timestamp":1660706127000},"page":"1325","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam"],"prefix":"10.3390","volume":"10","author":[{"given":"Duy Cuong","family":"Nguyen","sequence":"first","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Loi","family":"Dao","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Minh Dieu","family":"Truong","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu Huong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu Nga","family":"Phan","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha My","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Dung","family":"Pham","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan Bai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh Binh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Thuan","family":"Hoang","sequence":"additional","affiliation":[{"name":"Thai Binh University of Medicine and Pharmacy, Thai Binh 410000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"ref_1","unstructured":"WHO (2022, July 08). Issues Its First Emergency Use Validation for a COVID-19 Vaccine and Emphasizes Need for Equitable Global Access. Available online: https:\/\/www.who.int\/news\/item\/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access."},{"key":"ref_2","unstructured":"(2022, July 08). COVID-19 Vaccines Advice. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMc2108076","article-title":"Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers","volume":"385","author":"Lange","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-Breakthrough Infections to Time-from-Vaccine","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe Outcomes with Variants of Concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_6","unstructured":"(2022, August 05). Coronavirus (COVID-19) Vaccinations\u2014Our World in Data. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112816","DOI":"10.1016\/j.envres.2022.112816","article-title":"Emergence of SARS-CoV-2 Omicron (B.1.1.529) Variant, Salient Features, High Global Health Concerns and Strategies to Counter It amid Ongoing COVID-19 Pandemic","volume":"209","author":"Khandia","year":"2022","journal-title":"Environ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14760584.2021.1903879","article-title":"Effects of SARS-CoV-2 Variants on Vaccine Efficacy and Response Strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_9","unstructured":"CDC (2022, July 08). What to Expect after Getting a COVID-19 Vaccine, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html."},{"key":"ref_10","unstructured":"(2022, July 08). B\u1ed9 Y t\u1ebf\u2014C\u1ed5ng th\u00f4ng tin c\u1ee7a B\u1ed9 Y t\u1ebf v\u1ec1 \u0111\u1ea1i d\u1ecbch COVID-19, Available online: https:\/\/covid19.gov.vn\/."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Poniedzia\u0142ek, B., and Fal, A. (2021). Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. Vaccines, 9.","DOI":"10.3390\/vaccines9111286"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Babicki, M., and Mastalerz-Migas, A. (2022). Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. Vaccines, 10.","DOI":"10.3390\/vaccines10010068"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Al-Qerem, W., Al Bawab, A.Q., Hammad, A., Ling, J., and Alasmari, F. (2022). Willingness of the Jordanian Population to Receive a COVID-19 Booster Dose: A Cross-Sectional Study. Vaccines, 10.","DOI":"10.3390\/vaccines10030410"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Folcarelli, L., Miraglia del Giudice, G., Corea, F., and Angelillo, I.F. (2022). Intention to Receive the COVID-19 Vaccine Booster Dose in a University Community in Italy. Vaccines, 10.","DOI":"10.3389\/fpubh.2022.995382"},{"key":"ref_15","unstructured":"(2022, July 08). \u0110\u1ea9y nhanh ti\u00eam vaccine ph\u00f2ng COVID-19, tri\u1ec3n khai m\u0169i b\u1ed5 sung cho ng\u01b0\u1eddi \u0111\u1ee7 li\u1ec1u. Available online: https:\/\/ncov.vnanet.vn\/tin-tuc\/day-nhanh-tiem-vaccine-phong-covid-19-trien-khai-mui-bo-sung-cho-nguoi-du-lieu\/59b945a9-f7a0-4621-a837-4acc88958251."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful Selection of Variables in Logistic Regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"826327","DOI":"10.3389\/fmed.2022.826327","article-title":"Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021","volume":"9","author":"Zou","year":"2022","journal-title":"Front. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e227657","DOI":"10.1001\/jamanetworkopen.2022.7657","article-title":"Short-Term Adverse Events After the Third Dose of the BNT162b2 MRNA COVID-19 Vaccine in Adults 60 Years or Older","volume":"5","author":"Auster","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jgs.17812","article-title":"Adverse Events Following Third Dose of MRNA COVID-19 Vaccination among Nursing Home Residents Who Received the Primary Series","volume":"70","author":"Bardenheier","year":"2022","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.15585\/mmwr.mm7039e4","article-title":"Safety Monitoring of an Additional Dose of COVID-19 Vaccine\u2014United States, 12 August\u201319 September 2021","volume":"70","author":"Hause","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","article-title":"Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12\u201317 Years\u2014United States, 9 December 2021\u201320 February 2022","volume":"71","author":"Hause","year":"2022","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.15585\/mmwr.mm7107e1","article-title":"Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults\u2014United States, 22 September 2021\u20136 February 2022","volume":"71","author":"Hause","year":"2022","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 Vaccine Waning and Effectiveness and Side-Effects of Boosters: A Prospective Community Study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e227038","DOI":"10.1001\/jamanetworkopen.2022.7038","article-title":"Surveillance of Safety of 3 Doses of COVID-19 MRNA Vaccination Using Electronic Health Records","volume":"5","author":"Niesen","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Booth, A., Reed, A.B., Ponzo, S., Yassaee, A., Aral, M., Plans, D., Labrique, A., and Mohan, D. (2021). Population Risk Factors for Severe Disease and Mortality in COVID-19: A Global Systematic Review and Meta-Analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247461"},{"key":"ref_26","first-page":"1324","article-title":"Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster","volume":"327","author":"Kuehn","year":"2022","journal-title":"JAMA"},{"key":"ref_27","unstructured":"Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., and Amoako, D.G. (2022). Emergence of SARS-CoV-2 Omicron Lineages BA.4 and BA.5 in South Africa. Nat. Med., 1."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1325\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:10:32Z","timestamp":1760141432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081325"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081325","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}